Second-line therapy following osimertinib in metastatic EGFR-mutated non-small cell lung cancer at an academic medical center.

Authors: Michael Rafizadeh, Stephanie Bogdan, Jonathan W. Lee, Nasser K. Altorki, Xi K. Zhou, Ashish Saxena, Christine A Garcia, Bobak Parang

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e20653

Source: Full article

---

Abstract

e20653